BETACURE
Personalized diagnosis and treatment of hyperinsulinemic hypoglycaemia caused by beta-cell pathology
| Coordinatore | STICHTING KATHOLIEKE UNIVERSITEIT
Organization address
address: GEERT GROOTEPLEIN NOORD 9 contact info |
| Nazionalità Coordinatore | Netherlands [NL] |
| Totale costo | 7˙831˙646 € |
| EC contributo | 6˙000˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-04-01 - 2018-03-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
STICHTING KATHOLIEKE UNIVERSITEIT
Organization address
address: GEERT GROOTEPLEIN NOORD 9 contact info |
NL (NIJMEGEN) | coordinator | 995˙000.00 |
| 2 |
SURGVISION BV
Organization address
address: DALHUYSENSTRAAT 37 contact info |
NL (HEERENVEEN) | participant | 701˙000.00 |
| 3 |
ACADEMISCH ZIEKENHUIS GRONINGEN
Organization address
address: Hanzeplein 1 contact info |
NL (GRONINGEN) | participant | 661˙000.00 |
| 4 |
EXALOS AG
Organization address
address: WAGISTRASSE 21 contact info |
CH (SCHLIEREN) | participant | 497˙000.00 |
| 5 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 380˙000.00 |
| 6 |
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Organization address
address: Chariteplatz 1 contact info |
DE (BERLIN) | participant | 350˙000.00 |
| 7 |
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
Organization address
address: BATIMENT CE 3316 STATION 1 contact info |
CH (LAUSANNE) | participant | 350˙000.00 |
| 8 |
PAUL SCHERRER INSTITUT
Organization address
address: Villigen contact info |
CH (VILLIGEN PSI) | participant | 350˙000.00 |
| 9 | Concentris Research Management GmbH | DE | participant | 340˙000.00 |
| 10 |
UNIVERSITAETSSPITAL BASEL
Organization address
address: HEBELSTRASSE 32 contact info |
CH (BASEL) | participant | 310˙000.00 |
| 11 |
TURUN YLIOPISTO
Organization address
address: YLIOPISTONMAKI contact info |
FI (TURUN YLIOPISTO) | participant | 250˙000.00 |
| 12 |
UNIVERSITE DE LILLE II - DROIT ET SANTE
Organization address
address: RUE PAUL DUEZ 42 contact info |
FR (Lille) | participant | 250˙000.00 |
| 13 |
HELSINGIN YLIOPISTO
Organization address
address: YLIOPISTONKATU 4 contact info |
FI (HELSINGIN YLIOPISTO) | participant | 184˙000.00 |
| 14 |
piCHEM Forschungs und Entwicklungsgmbh
Organization address
address: Kahngasse 20 contact info |
AT (Graz) | participant | 142˙000.00 |
| 15 |
UNIVERSITAET BERN
Organization address
address: Hochschulstrasse 4 contact info |
CH (BERN) | participant | 120˙000.00 |
| 16 |
EANM FORSCHUNGS GMBH
Organization address
address: HOLLANDSTRASSE 14 contact info |
AT (WIEN) | participant | 60˙000.00 |
| 17 |
TransMIT Gesellschaft fuer Technologietransfer mbH
Organization address
address: Kerkrader Strasse 3 contact info |
DE (GIESSEN) | participant | 60˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Background: Hyperinsulinaemic hypoglycaemia (HH) is a potentially lethal disease caused by over functioning beta cells derived from the pancreatic islets of Langerhans. Lethal HH and brain damage is a problem especially in infants with congenital HH. Current therapeutic approaches are associated with severe side effects/morbidity (diabetes, exocrine pancreas insufficiency etc.) considered acceptable in relation to the lethal outcome of HH although massively reducing quality of life and also life expectancy. Aims and objectives: In order to significantly improve therapy of this awful disorder, we propose to develop a simultaneous imaging/therapy platform allowing diagnostic imaging as well as image guided surgical, photodynamic or radiopeptide therapy to selectively resect/destroy diseased beta cells. This platform will enable delivery of patient-individual tailored therapy, increasing cure rate while significantly reducing or even avoiding side effects. The platform will integrate information from pre-clinical imaging for optimal therapy planning with intra-operative imaging for image guided surgery. By implementation of extended field optical coherence tomography, information on a histopathological level will allow increased precision of therapy. Highly innovative photodynamic therapy will enable selective (endoscopic) destruction of diseased beta cells without resection of pancreatic tissue. Outcome: Our highly-innovative integrated imaging/therapy (“theranostic”) platform will allow diagnosis and monitoring of disease, support and guide therapeutic intervention, predict outcome of intervention and individual prognosis. This technology will massively improve therapy, especially in infants, by improving cure rates while significantly reducing morbidity for improved quality of life and increased life expectancy. We will contribute to the goals of the International Rare Diseases Research Consortium (IRDiRC): 200 new therapies.'